After analyzing the file provided by the manufacturer, the Medecines and Healthcare Products regulatory Agency (MHRA) announced on Thursday, November 4 that molnupiravir oral therapy was “ safe and efficient “. Requests from the Food and Drug Administration (FDA) in the USA and with theEuropean Medecines Agency are under review. The US is expected to give its response on November 30.
Molnupiravir: a new oral treatment against Covid-19 soon available!
Clinical trials on molnupiravir have shown its ability to decrease the risk of hospitalizations, whatever the variant. Avoiding saturation in hospital services: this is the challenge of the health policies pursued by most countries in the world.
—
Early treatment for patients at risk
This drug is the first oral treatment for Covid-19. In contrary to the antibody cocktails already available, this medicine can be prescribed in town and administered outside the hospital. It is indicated in mild to moderate forms, in adults with at least one risk factor for a severe form of the disease (diabetes, obesity, heart disease, people over 60 years old, etc.).
Coronavirus: more than 80% of people in intensive care are overweight
It should be administered as soon as possible, within the first five days after the onset of symptoms. The dosage is 800 mg twice a day for five days.
The laboratory had started production before the authorization and declares to be able to provide 10 million complete treatment regimens by the end of 2021. France, for its part, has pre-ordered 50,000 doses of this treatment. With the upsurge in the number of cases in recent days in France, any additional weapon in the fight against the pandemic is welcome.
Read more on Futura “class =” link rapid-noclick-resp “>> Read more on Futura
Read also on Futura
–
